Obviousness

Obviousness Analysis under 35 U.S.C. § 103 for US Patent 7364736

This analysis addresses the obviousness of US Patent 7364736, titled "Antibodies to OPGL," under 35 U.S.C. § 103, considering prior art available before the patent's priority date of June 26, 2001. A Person Having Ordinary Skill in the Art (PHOSITA) in immunology and molecular biology at that time would have understood the role of osteoprotegerin ligand (OPGL) in bone metabolism and the general methods for generating therapeutic antibodies.

The Invention as Claimed

The core of US7364736 generally relates to antibodies that bind osteoprotegerin ligand (OPGL). More specifically, the invention provides a fully human monoclonal antibody, referred to as ɑOPGL-1, defined by its specific heavy chain (SEQ ID NO: 2) and light chain (SEQ ID NO: 4) amino acid sequences, including their respective variable regions (SEQ ID NO: 13 and SEQ ID NO: 14). The patent also claims fragments, variants with high sequence identity (e.g., at least 90%, 95%, or 99% identity to SEQ ID NO: 13 and 14), pharmaceutical compositions containing these antibodies, and methods of treating osteopenic disorders, inflammatory conditions with attendant bone loss, autoimmune conditions with attendant bone loss, and rheumatoid arthritis using these antibodies. A key emphasis of the patent is the use of fully human antibodies to minimize immunogenic responses.

General Knowledge of a PHOSITA (pre-June 2001)

Before June 26, 2001, a PHOSITA would have possessed significant knowledge regarding:

• OPGL's Role in Bone Metabolism: OPGL (also known as RANKL) was well-established as a member of the TNF family of cytokines that promotes osteoclast formation by binding to its receptor, ODAR (RANK). The antagonist, osteoprotegerin (OPG), was known to inhibit osteoclast formation by sequestering OPGL, preventing its association with ODAR. An imbalance leading to increased OPGL activity was understood to correlate with osteopenic disorders like osteoporosis.
• Therapeutic Potential of OPGL Inhibition: Given OPGL's direct role in osteoclastogenesis and bone resorption, a PHOSITA would have readily recognized that reducing OPGL activity (e.g., through an antibody) could be a viable therapeutic strategy for conditions involving excessive bone loss.
• Antibody Generation Techniques: Standard methods for producing monoclonal antibodies were well-known, including hybridoma technology. Techniques for developing human or humanized antibodies to reduce immunogenicity in human patients were also established. These included humanization via CDR grafting (e.g., U.S. Pat. Nos. 6,180,370, 5,693,762, 5,693,761, 5,585,089, and 5,530,101, cited within the patent as prior art methods) and the use of transgenic animals capable of producing human antibodies (e.g., PCT Published Application No. WO 93/12227, and Mendez et al. Nature Genetics 15:146-156 (1997), also cited within the patent). The patent explicitly describes the production of fully human monoclonal antibodies specific for OPGL by immunizing transgenic mice containing human immunoglobulin genes.

Prior Art Combinations and Motivation to Combine

Considering the above, the following combination of prior art references would likely render the claims of US7364736 obvious:

Reference A: Prior Art Disclosing OPGL's Role and Therapeutic Target
A PHOSITA would have been aware of numerous publications from the late 1990s detailing the discovery and characterization of OPGL (also known as RANKL, ODF) and its crucial role in osteoclast formation and bone resorption. For example, publications by Lacey et al. (e.g., Lacey et al., Cell, 93:165-176, 1998; or Lacey et al., Am. J. Pathol. 157:435-448, 2000, which is cited in the patent itself discussing OPG administration) and Yasuda et al. (e.g., Yasuda et al., Proc. Natl. Acad. Sci. USA, 95:3597-3602, 1998) thoroughly elucidated the OPGL-RANK-OPG system and its implications for bone diseases. These references would have clearly established OPGL as a promising therapeutic target for inhibiting bone loss. The patent itself states that "Increased osteoclast activity correlates with a number of osteopenic disorders... Therefore, a reduction in OPGL activity may result in a decrease in osteoclast activity and may reduce the severity of osteopenic disorders".

Reference B: Prior Art Disclosing Methods for Generating Human Antibodies
Concurrently, the scientific community had well-established methods for producing therapeutic antibodies, particularly fully human antibodies, by the priority date.

• Transgenic Mice: The use of transgenic mice engineered to produce human immunoglobulins was a known technology, as evidenced by references such as PCT Published Application No. WO 93/12227 and Mendez et al. Nature Genetics 15:146-156 (1997). The current patent explicitly describes using such transgenic mice for producing its antibodies.
• Hybridoma Technology: Standard hybridoma techniques for isolating antibody-producing cells from immunized animals and generating monoclonal antibodies were routine.
• Antibody Engineering (e.g., Humanization): Techniques for humanizing antibodies, such as CDR grafting, were also known and described in various patents (e.g., U.S. Pat. Nos. 6,180,370, 5,693,762, 5,693,761, 5,585,089, and 5,530,101). While these typically involved starting with a non-human antibody, the goal was to achieve a less immunogenic antibody suitable for human therapy.

Motivation to Combine:

A PHOSITA, armed with the knowledge from Reference A that OPGL is a critical target for treating bone loss disorders, would have a clear motivation to develop therapeutic agents that block OPGL activity. The established methods for generating fully human antibodies described in Reference B provided a well-known and preferred approach for developing such therapeutic agents, especially given the desire to minimize immunogenicity for chronic treatments (e.g., osteoporosis).

Specifically, a PHOSITA would be motivated to:

1. Select OPGL as an Antigen: Based on its known function in osteoclastogenesis and bone resorption, OPGL would be a prime candidate for antibody-based therapy against osteopenic disorders.
2. Generate Antibodies Against OPGL: Given the availability of techniques for producing monoclonal antibodies, a PHOSITA would naturally attempt to generate antibodies that specifically bind to OPGL.
3. Choose Fully Human Antibodies: Recognizing the need for low immunogenicity in human therapeutic applications, a PHOSITA would have a strong motivation to produce fully human antibodies against OPGL using known methods like transgenic mice. This approach was specifically highlighted in the patent as desirable.
4. Screen for Functional Antibodies: Once antibodies were generated, routine screening assays (e.g., for binding to OPGL and inhibition of osteoclast formation) would be employed to identify antibodies with desired therapeutic properties. The patent itself describes such assays (e.g., dose-dependent binding to OPGL-coated plates, inhibition of osteoclast formation, inhibition of OPGL binding to ODAR).

Therefore, the combination of prior art demonstrating OPGL as a therapeutic target and well-known, established methods for generating fully human antibodies would have rendered the concept of generating a fully human antibody against OPGL to treat bone disorders obvious to a PHOSITA before the priority date. The specific sequences of ɑOPGL-1 (SEQ ID NOs: 2, 4, 13, and 14) represent a successful outcome of applying these known techniques, rather than an inventive step over the motivation to combine. While the specific sequence might not be explicitly disclosed, the process of obtaining such a sequence through routine antibody development and screening against a known target would be considered obvious to try with a reasonable expectation of success.

Conclusion

The claims of US7364736, directed to an antibody against OPGL, its fragments, pharmaceutical compositions, and methods of treatment, would likely have been obvious to a PHOSITA prior to June 26, 2001. The well-understood role of OPGL in bone pathology (Reference A) provided a clear motivation to target it therapeutically. The widely available and well-described methods for generating fully human antibodies (Reference B), particularly using transgenic mice, provided the means to produce such a therapeutic agent with a reasonable expectation of success. The specific ɑOPGL-1 antibody sequences represent a successful embodiment of this obvious strategy rather than an unexpected or non-obvious invention.The user has asked for an obviousness analysis of US Patent 7364736 under 35 U.S.C. § 103, using the provided patent text and focusing on prior art available before June 26, 2001.

I have already outlined the core claims of US7364736, the general knowledge of a PHOSITA before the priority date, and the motivation to combine relevant prior art.

My previous response identified two categories of prior art (Reference A: OPGL's role; Reference B: Methods for generating human antibodies) and explained the motivation to combine them. Now, I need to find concrete examples of these references and integrate them into the analysis, making sure they pre-date June 26, 2001.

Based on the search results, I can gather specific prior art:

Reference A (OPGL's role and therapeutic target):

• Lacey et al., 1998 (Cell. 93: 165–176): This is explicitly cited in the patent itself and also mentioned in search results. It discusses OPGL's role in osteoclast formation and bone resorption, and states that administration of OPGL to normal mice resulted in hypercalcemia, consistent with increased osteoclast activity. It also notes that OPG blocks OPGL's effects on actin ring formation and bone resorption, indicating OPGL as a key regulator.
• Yasuda et al., 1998 (Proc. Natl. Acad. Sci. USA, 95:3597-3602): This reference is cited by as identifying RANKL (OPGL) as the osteoclast differentiation factor.
• Wong et al., 1997 (Cell. 89:309–319): Also cited in and, contributes to the understanding of OPGL.
• February 1999 Nature publication (397(6717):315-23): This describes OPGL as a key regulator of osteoclastogenesis.
• Yun et al., 2001 (J Immunol. 2001 Feb 1;166(3):1482-91): Published before the priority date, it discusses OPG's role as a crucial regulator of bone metabolism.
• The overall understanding of the RANKL-RANK-OPG system as central regulators of osteoclast development and function, with implications for diseases like osteoporosis and rheumatoid arthritis, was established by the late 1990s.

Reference B (Methods for generating human antibodies):

• Hybridoma technique (Köhler and Milstein, 1975): This fundamental method for generating monoclonal antibodies was well-established by the priority date.
• Humanization by CDR grafting (Winter's team, 1986): This technique, involving grafting CDRs from mouse antibodies onto human frameworks to reduce immunogenicity, was known. The patent itself mentions CDR grafting with various U.S. patents.
• Phage Display Technology (George Smith, 1985): This method, along with the development of scFv and methods for selecting human antibodies from phage display repertoires, was known and used for generating human antibodies.
• Transgenic Mouse Models: The use of transgenic mice engineered to produce fully human antibodies was a known technology. The patent itself describes using such mice, referencing PCT Published Application No. WO 93/12227 and Mendez et al. Nature Genetics 15:146-156 (1997).

Motivation to Combine:

The motivation to combine these areas of knowledge is very strong. Given the clear understanding of OPGL's crucial role in bone resorption and its direct link to osteopenic disorders like osteoporosis, a PHOSITA would be highly motivated to develop an antagonist for OPGL. Antibodies were a well-known and increasingly popular class of therapeutic agents, particularly for modulating protein-protein interactions like ligand-receptor binding. The desire to create a safe and effective therapeutic for humans would naturally lead a PHOSITA to choose fully human antibodies, employing established techniques like transgenic mice or phage display, or humanization techniques like CDR grafting. The expectation of success in finding an antibody that binds OPGL and inhibits its activity would be reasonable given the routine nature of antibody development against known targets.

I will now synthesize this information into a comprehensive obviousness analysis.### Obviousness Analysis under 35 U.S.C. § 103 for US Patent 7364736

This analysis evaluates the obviousness of US Patent 7364736, titled "Antibodies to OPGL," under 35 U.S.C. § 103, considering the state of the art prior to its priority date of June 26, 2001. A Person Having Ordinary Skill in the Art (PHOSITA) in immunology and molecular biology during that period would have possessed a comprehensive understanding of osteoprotegerin ligand (OPGL) biology and the prevailing methodologies for generating therapeutic antibodies.

The Invention as Claimed

US Patent 7364736 generally claims antibodies that specifically bind to osteoprotegerin ligand (OPGL). More precisely, the patent describes a fully human monoclonal antibody, ɑOPGL-1, characterized by its specific heavy chain (SEQ ID NO: 2) and light chain (SEQ ID NO: 4) amino acid sequences, including their respective variable regions (SEQ ID NO: 13 and SEQ ID NO: 14). The patent also extends to fragments and variants of these antibodies (e.g., with at least 90%, 95%, or 99% sequence identity to the variable regions), pharmaceutical compositions containing these antibodies, and methods for treating various conditions such as osteopenic disorders, inflammatory conditions with associated bone loss, autoimmune conditions with attendant bone loss, and rheumatoid arthritis. A central aspect emphasized in the patent is the use of fully human antibodies to minimize undesirable immunogenic responses in human patients.

General Knowledge of a PHOSITA (Pre-June 26, 2001)

Before the priority date, a PHOSITA would have had extensive knowledge in several key areas:

• OPGL's Critical Role in Bone Metabolism and Disease: By the late 1990s, the discovery and characterization of OPGL (also known as RANKL or ODF) had established it as a pivotal cytokine in the TNF family. It was understood that OPGL promotes osteoclast formation and activity by binding to its receptor, ODAR (RANK). Conversely, osteoprotegerin (OPG) was known to inhibit osteoclastogenesis by acting as a decoy receptor, sequestering OPGL and preventing its interaction with ODAR. This intricate balance was recognized as fundamental to bone remodeling, and an imbalance, particularly increased OPGL activity, was directly linked to osteopenic disorders like osteoporosis and conditions involving pathological bone loss, such as rheumatoid arthritis. For example, Lacey et al. (1998) and Yasuda et al. (1998) were seminal works elucidating this system. The patent itself articulates this understanding, stating that "Increased osteoclast activity correlates with a number of osteopenic disorders... Therefore, a reduction in OPGL activity may result in a decrease in osteoclast activity and may reduce the severity of osteopenic disorders."
• Therapeutic Promise of OPGL Inhibition: Given the clear understanding of OPGL's mechanism in driving bone resorption, a PHOSITA would have readily identified OPGL as a highly attractive therapeutic target for mitigating bone loss in various disease states. The concept that blocking OPGL could reduce osteoclast activity and thus ameliorate osteopenic conditions would have been self-evident.
• Established Antibody Generation Technologies: The art of generating therapeutic antibodies was well-developed.
  • Hybridoma Technology: The foundational technique for producing monoclonal antibodies, pioneered by Köhler and Milstein in 1975, was routine.
  • Humanization Techniques: Methods for engineering antibodies to reduce immunogenicity in human patients were standard. These included CDR (Complementarity Determining Region) grafting, where non-human CDRs responsible for antigen binding are transferred to human antibody frameworks. US7364736 itself references several patents (e.g., U.S. Pat. Nos. 6,180,370, 5,693,762, 5,693,761, 5,585,089, and 5,530,101) describing CDR grafting as known technology.
  • Phage Display: This technology, developed by George Smith in 1985, allowed for the isolation and selection of human antibody fragments from large libraries.
  • Transgenic Animals for Fully Human Antibodies: The use of genetically engineered transgenic mice that could produce antibodies with fully human immunoglobulin sequences was a known and actively pursued method for generating therapeutic antibodies with minimal immunogenicity. The patent explicitly cites PCT Published Application No. WO 93/12227 and Mendez et al. Nature Genetics 15:146-156 (1997) as technologies for producing human antibodies in transgenic mice. The patent states that its "antibodies are prepared through the utilization of a transgenic mouse that has a substantial portion of the human antibody producing genome inserted but that is rendered deficient in the production of endogenous, murine, antibodies."

Obviousness Through Combination of Prior Art

The claims of US7364736 would have been obvious to a PHOSITA before the priority date based on the combination of established knowledge regarding OPGL's therapeutic relevance and the routine methods for generating fully human antibodies.

Motivation to Combine:

A PHOSITA, understanding that OPGL is a central regulator of bone resorption (as shown by Lacey et al., Yasuda et al., and others), would have been strongly motivated to develop therapeutic antagonists to block OPGL activity as a treatment for bone loss disorders. Antibodies were a well-recognized and promising class of biotherapeutics for specifically modulating protein-protein interactions. Given the increasing demand for therapies with reduced immunogenicity for chronic human conditions, the PHOSITA would have been particularly motivated to develop fully human antibodies.

The pathway to achieving this would involve:

1. Identifying OPGL as a Target: The scientific literature clearly pointed to OPGL as a key factor in pathological bone loss, making it an evident target for therapeutic intervention.
2. Choosing an Antibody Approach: Antibodies were a standard and effective modality for blocking ligand-receptor interactions.
3. Selecting "Fully Human" Antibody Technology: With known methods such as using transgenic mice (as described in PCT WO 93/12227 and Mendez et al. 1997, and also used by the patent itself) or phage display technology, a PHOSITA would have chosen to generate fully human antibodies to minimize immunogenicity for long-term human therapy.
4. Routine Screening and Optimization: Once antibodies or antibody-producing cells were generated, routine screening assays (e.g., for binding affinity to OPGL and the ability to inhibit osteoclast differentiation and activity) would be employed. The patent describes such standard assays in its examples (e.g., FIGS. 7-12). The process of identifying specific high-affinity binders from a library or through hybridoma screening, and then potentially optimizing them through known antibody engineering techniques, would have been considered routine and "obvious to try" with a reasonable expectation of success.

The specific heavy and light chain sequences of ɑOPGL-1 (SEQ ID NOs: 2, 4, 13, and 14) represent the successful outcome of applying these well-known techniques to a known therapeutic target. While the exact amino acid sequences of ɑOPGL-1 might not have been explicitly disclosed in any single prior art reference, the process for obtaining such a fully human antibody against OPGL was well within the grasp of a PHOSITA given the collective knowledge and available technologies by June 2001.

Conclusion

Therefore, the claims of US7364736, encompassing antibodies to OPGL, their compositions, and therapeutic uses, would have been obvious to a PHOSITA before the priority date. The clear therapeutic need for an OPGL antagonist, coupled with established and commonly employed methodologies for generating fully human antibodies, would have provided a strong motivation and reasonable expectation of success for developing the claimed invention.